CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 100.0%

Compliant submissions 2

Incompliant submissions 0

Total trials 2

My Organizations' Clinical Trials

Showing 1325 of 2003 entries

View as:

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Phase: N/A Priority: Normal

NCT ID: NCT01748149 Org: User:

Start: 04/29/14 End: 12/31/25 Due: 12/31/26

Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies

Phase: N/A Priority: Normal

NCT ID: NCT00581763 Org: User:

Start: 05/31/01 End: 12/20/19 Due: 12/20/20

Infant Mortality Reduction by the Mass Administration of Azithromycin

Phase: N/A Priority: Normal

NCT ID: NCT04716712 Org: User:

Start: 10/04/21 End: 01/30/26 Due: 01/30/27

The TARANG Intervention

Phase: N/A Priority: Normal

NCT ID: NCT06320964 Org: User:

Start: 07/14/23 End: 01/21/24 Due: 01/21/25

Paired Integrative Exercise Program for People With Dementia and Caregivers

Phase: N/A Priority: Normal

NCT ID: NCT02729311 Org: User:

Start: 07/01/16 End: 12/31/18 Due: 12/31/19

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Phase: N/A Priority: Normal

NCT ID: NCT05746182 Org: User:

Start: 04/07/23 End: 12/31/25 Due: 12/31/26

Bone Quality by vQCT and HR-pQCT:Translation to Multi-center Clinical Research

Phase: N/A Priority: Normal

NCT ID: NCT01544660 Org: User:

Start: 04/30/12 End: 03/31/14 Due: 03/31/15

Achieving Chronic Care equiTy by leVeraging the Telehealth Ecosystem

Phase: N/A Priority: Normal

NCT ID: NCT06598436 Org: User:

Start: 11/04/24 End: 09/30/28 Due: 09/30/29

Ultrasound Neuromodulation in Essential Tremor

Phase: N/A Priority: Normal

NCT ID: NCT06610877 Org: User:

Start: 10/31/24 End: 03/31/27 Due: 03/31/28

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Phase: N/A Priority: Normal

NCT ID: NCT05746208 Org: User:

Start: 07/17/23 End: 10/31/27 Due: 10/31/28

An Adaptive Intervention for Depression Among Latinos Living With HIV

Phase: N/A Priority: Normal

NCT ID: NCT03668379 Org: User:

Start: 02/26/20 End: 08/28/22 Due: 08/28/23

Decreasing Over Screening and Treatment of Cervical Precancers in Young Women

Phase: N/A Priority: Normal

NCT ID: NCT02270021 Org: User:

Start: 07/24/14 End: 08/30/19 Due: 08/30/20

Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus

Phase: N/A Priority: Normal

NCT ID: NCT00187564 Org: User:

Start: 08/31/04 End: 10/31/05 Due: 10/31/06

Pilot Study of Pancreatic Cancer Screening

Phase: N/A Priority: Normal

NCT ID: NCT05058846 Org: User:

Start: 01/20/22 End: 01/31/32 Due: 01/31/33

Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease

Phase: N/A Priority: Normal

NCT ID: NCT00415272 Org: User:

Start: - End: 07/31/07 Due: 07/31/08

Health Enhancement And Resilience Training

Phase: N/A Priority: Normal

NCT ID: NCT01959126 Org: User:

Start: 05/31/13 End: 11/30/15 Due: 11/30/16

Evaluating Multivariate MRI Maps of Body Awareness

Phase: N/A Priority: Normal

NCT ID: NCT03344081 Org: User:

Start: 06/01/16 End: 07/11/19 Due: 07/11/20

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Phase: N/A Priority: Normal

NCT ID: NCT04190056 Org: User:

Start: 03/11/21 End: 06/15/23 Due: 06/15/24

Developing Individualized Strategies to Prevent Nausea and Vomiting

Phase: N/A Priority: Normal

NCT ID: NCT01393288 Org: User:

Start: 11/30/13 End: 11/30/15 Due: 11/30/16

Activity Trackers for Improving BP

Phase: N/A Priority: Normal

NCT ID: NCT03325426 Org: User:

Start: 06/01/17 End: 01/01/21 Due: 01/01/22

Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE)

Phase: N/A Priority: Normal

NCT ID: NCT02403752 Org: User:

Start: 03/31/15 End: 07/31/18 Due: 07/31/19

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal

NCT ID: NCT02215161 Org: User:

Start: 09/02/14 End: 04/02/18 Due: 04/02/19

Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00678015 Org: User:

Start: 05/31/08 End: 06/30/11 Due: 06/30/12

Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM

Phase: N/A Priority: Normal

NCT ID: NCT00370006 Org: User:

Start: 09/30/06 End: 08/31/07 Due: 08/31/08

ICU Patient and Family Comfort Study

Phase: N/A Priority: Normal

NCT ID: NCT00798941 Org: User:

Start: 02/28/09 End: 01/31/10 Due: 01/31/11

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas	NCT01748149	University of California, San Francisco	user2@example.com	None	2014-04-29	2025-12-31	2026-12-31	-	-	2025-07-14
Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies	NCT00581763	University of California, San Francisco	user2@example.com	None	2001-05-31	2019-12-20	2020-12-20	-	-	2025-07-14
Infant Mortality Reduction by the Mass Administration of Azithromycin	NCT04716712	University of California, San Francisco	user2@example.com	None	2021-10-04	2026-01-30	2027-01-30	-	-	2025-07-14
The TARANG Intervention	NCT06320964	University of California, San Francisco	user2@example.com	None	2023-07-14	2024-01-21	2025-01-21	-	-	2025-07-14
Paired Integrative Exercise Program for People With Dementia and Caregivers	NCT02729311	University of California, San Francisco	user2@example.com	None	2016-07-01	2018-12-31	2019-12-31	-	-	2025-07-14
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms	NCT05746182	University of California, San Francisco	user2@example.com	None	2023-04-07	2025-12-31	2026-12-31	-	-	2025-07-14
Bone Quality by vQCT and HR-pQCT:Translation to Multi-center Clinical Research	NCT01544660	University of California, San Francisco	user2@example.com	None	2012-04-30	2014-03-31	2015-03-31	-	-	2025-07-14
Achieving Chronic Care equiTy by leVeraging the Telehealth Ecosystem	NCT06598436	University of California, San Francisco	user2@example.com	None	2024-11-04	2028-09-30	2029-09-30	-	-	2025-07-14
Ultrasound Neuromodulation in Essential Tremor	NCT06610877	University of California, San Francisco	user2@example.com	None	2024-10-31	2027-03-31	2028-03-31	-	-	2025-07-14
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors	NCT05746208	University of California, San Francisco	user2@example.com	None	2023-07-17	2027-10-31	2028-10-31	-	-	2025-07-14
An Adaptive Intervention for Depression Among Latinos Living With HIV	NCT03668379	University of California, San Francisco	user2@example.com	None	2020-02-26	2022-08-28	2023-08-28	-	-	2025-07-14
Decreasing Over Screening and Treatment of Cervical Precancers in Young Women	NCT02270021	University of California, San Francisco	user2@example.com	None	2014-07-24	2019-08-30	2020-08-30	-	-	2025-07-14
Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus	NCT00187564	University of California, San Francisco	user2@example.com	None	2004-08-31	2005-10-31	2006-10-31	-	-	2025-07-14
Pilot Study of Pancreatic Cancer Screening	NCT05058846	University of California, San Francisco	user2@example.com	None	2022-01-20	2032-01-31	2033-01-31	-	-	2025-07-14
Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease	NCT00415272	University of California, San Francisco	user2@example.com	None	-	2007-07-31	2008-07-31	-	-	2025-07-14
Health Enhancement And Resilience Training	NCT01959126	University of California, San Francisco	user2@example.com	None	2013-05-31	2015-11-30	2016-11-30	-	-	2025-07-14
Evaluating Multivariate MRI Maps of Body Awareness	NCT03344081	University of California, San Francisco	user2@example.com	None	2016-06-01	2019-07-11	2020-07-11	-	-	2025-07-14
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer	NCT04190056	University of California, San Francisco	user2@example.com	None	2021-03-11	2023-06-15	2024-06-15	-	-	2025-07-14
Developing Individualized Strategies to Prevent Nausea and Vomiting	NCT01393288	University of California, San Francisco	user2@example.com	None	2013-11-30	2015-11-30	2016-11-30	-	-	2025-07-14
Activity Trackers for Improving BP	NCT03325426	University of California, San Francisco	user2@example.com	None	2017-06-01	2021-01-01	2022-01-01	-	-	2025-07-14
Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE)	NCT02403752	University of California, San Francisco	user2@example.com	None	2015-03-31	2018-07-31	2019-07-31	-	-	2025-07-14
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer	NCT02215161	University of California, San Francisco	user2@example.com	None	2014-09-02	2018-04-02	2019-04-02	-	-	2025-07-14
Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer	NCT00678015	University of California, San Francisco	user2@example.com	None	2008-05-31	2011-06-30	2012-06-30	-	-	2025-07-14
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM	NCT00370006	University of California, San Francisco	user2@example.com	None	2006-09-30	2007-08-31	2008-08-31	-	-	2025-07-14
ICU Patient and Family Comfort Study	NCT00798941	University of California, San Francisco	user2@example.com	None	2009-02-28	2010-01-31	2011-01-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance